Cardiovascular Drugs and Therapy

, Volume 27, Issue 2, pp 125–132

Liposomal Amiodarone Augments Anti-arrhythmic Effects and Reduces Hemodynamic Adverse Effects in an Ischemia/Reperfusion Rat Model

  • Hiroyuki Takahama
  • Hirokazu Shigematsu
  • Tomohiro Asai
  • Takashi Matsuzaki
  • Shoji Sanada
  • Hai Ying Fu
  • Keiji Okuda
  • Masaki Yamato
  • Hiroshi Asanuma
  • Yoshihiro Asano
  • Masanori Asakura
  • Naoto Oku
  • Issei Komuro
  • Masafumi Kitakaze
  • Tetsuo Minamino
ORIGINAL ARTICLE

Abstract

Purpose

Although amiodarone is recognized as the most effective anti-arrhythmic drug available, it has negative hemodynamic effects. Nano-sized liposomes can accumulate in and selectively deliver drugs to ischemic/reperfused (I/R) myocardium, which may augment drug effects and reduce side effects. We investigated the effects of liposomal amiodarone on lethal arrhythmias and hemodynamic parameters in an ischemia/reperfusion rat model.

Methods and Results

We prepared liposomal amiodarone (mean diameter: 113 ± 8 nm) by a thin-film method. The left coronary artery of experimental rats was occluded for 5 min followed by reperfusion. Ex vivo fluorescent imaging revealed that intravenously administered fluorescent-labeled nano-sized beads accumulated in the I/R myocardium. Amiodarone was measurable in samples from the I/R myocardium when liposomal amiodarone, but not amiodarone, was administered. Although the intravenous administration of amiodarone (3 mg/kg) or liposomal amiodarone (3 mg/kg) reduced heart rate and systolic blood pressure compared with saline, the decrease in heart rate or systolic blood pressure caused by liposomal amiodarone was smaller compared with a corresponding dose of free amiodarone. The intravenous administration of liposomal amiodarone (3 mg/kg), but not free amiodarone (3 mg/kg), 5 min before ischemia showed a significantly reduced duration of lethal arrhythmias (18 ± 9 s) and mortality (0 %) during the reperfusion period compared with saline (195 ± 42 s, 71 %, respectively).

Conclusions

Targeting the delivery of liposomal amiodarone to ischemic/reperfused myocardium reduces the mortality due to lethal arrhythmia and the negative hemodynamic changes caused by amiodarone. Nano-size liposomes may be a promising drug delivery system for targeting I/R myocardium with cardioprotective agents.

Keywords

Liposome Amiodarone Lethal arrhythmia Ischemia Reperfusion 

References

  1. 1.
    Di Diego JM, Antzelevitch C. Ischemic ventricular arrhythmias: experimental models and their clinical relevance. Hear Rhythm. 2011;8:1963–8.CrossRefGoogle Scholar
  2. 2.
    Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35:13–29.PubMedCrossRefGoogle Scholar
  3. 3.
    Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298:1312–22.PubMedCrossRefGoogle Scholar
  4. 4.
    Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Muticenter Investigators Group. Circulation. 1995;92:3264–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Podrid PJ. Amiodarone; reevaluation of an old drug. Ann Intern Med. 1995;122:689–700.PubMedGoogle Scholar
  6. 6.
    Shiga T, Tanaka T, Irie S, Hagiwara N, Kasanuki H. Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. Hear Vessel. 2011;26:274–81.CrossRefGoogle Scholar
  7. 7.
    Wenzel V, Russo SG, Arntz HR, et al. [Comments on the 2010 guidelines on cardiopulmonary resuscitation of the European Resuscitation Council.]. Anaesthesist. 2010.Google Scholar
  8. 8.
    Elizari MV, Martínez JM, Belziti C, et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. GEMICA study investigators, GEMA Group, Buenos Aires, Argentina. Grupo de Estudios Multicentricos en Argentina. Eur Heart J. 2000;21:198–205.PubMedCrossRefGoogle Scholar
  9. 9.
    Hu K, Gaudron P, Ertl G. Effects of high- and low-dose amiodarone on mortality, left ventricular remodeling, and hemodynamics in rats with experimental myocardial infarction. J Cardiovasc Pharmacol. 2004;44:627–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Semalty A, Semalty M, Rawat BS, Singh D, Rawat MS. Pharmacosomes: the lipid-based new drug delivery system. Expert Opin Drug Deliv. 2009;6:599–612.PubMedCrossRefGoogle Scholar
  11. 11.
    Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129–38.PubMedCrossRefGoogle Scholar
  12. 12.
    Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30:592–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Horwitz LD, Kaufman D, Keller MW, Kong Y. Time course of coronary endothelial healing after injury due to ischemia and reperfusion. Circulation. 1994;90:2439–47.PubMedCrossRefGoogle Scholar
  14. 14.
    Dauber IM, VanBenthuysen KM, McMurtry IF, et al. Functional coronary microvascular injury evident as increased permeability due to brief ischemia and reperfusion. Circ Res. 1990;66:986–98.PubMedCrossRefGoogle Scholar
  15. 15.
    Galagudza MM, Korolev DV, Sonin DL, et al. Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization, natural biodistribution, and acute toxicity. Int J Nanomedicine. 2010;5:231–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Takahama H, Minamino T, Asanuma H, et al. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol. 2009;53:709–17.PubMedCrossRefGoogle Scholar
  17. 17.
    Riva E, Hearse DJ. Anti-arrhythmic effects of amiodarone and desethylamiodarone on malignant ventricular arrhythmias arising as a consequence of ischaemia and reperfusion in the anaesthetised rat. Cardiovasc Res. 1989;23:331–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Canyon SJ, Dobson GP. Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat. Am J Physiol Heart Circ Physiol. 2004;287:H1286–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Plomp TA, Wiersinga WM, Maes RA. Tissue distribution of amiodarone and desethylamiodarone in rats after repeated oral administration of various amiodarone dosages. Arzneimittelforschung. 1985;35:1805–10.PubMedGoogle Scholar
  20. 20.
    Feige JN, Sage D, Wahli W, Desvergne B, Gelman L. PixFRET, an ImageJ plug-in for FRET calculation that can accommodate variations in spectral bleed-trhoughs. Microsc Res Tech. 2005;68:51–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Opitz CF, Mitchell GF, Pfeffer MA, Pfeffer JM. Arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats. Circulation. 1995;92:253–61.PubMedCrossRefGoogle Scholar
  22. 22.
    Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268:235–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Theodossiou TA, Galanou MC, Paleos CM. Novel amiodarone-doxorubicin cocktail liposomes enhance doxorubicin retention and cytotoxicity in DU145 human prostate carcinoma cells. J Med Chem. 2008;51:6067–74.PubMedCrossRefGoogle Scholar
  24. 24.
    Elhasi S, Astaneh R, Lavasanifar A. Solubilization of an amphiphilic drug by poly(ethylene oxide)-block-poly(ester) micelles. Eur J Pharm Biopharm. 2007;65:406–13.PubMedCrossRefGoogle Scholar
  25. 25.
    Kamiya K, Nishiyama A, Yasui K, Hojo M, Sanguinetti MC, Kodama I. Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation. 2001;9:1317–24.CrossRefGoogle Scholar
  26. 26.
    Kishida S, Nakajima T, Ma J, et al. Amiodarone and N-desethylamiodarone enhance endothelial nitric oxide production in human endothelial cells. Int Heart J. 2006;47:85–93.PubMedCrossRefGoogle Scholar
  27. 27.
    Ide T, Tsutsui H, Kinugawa S, Utsumi H, Takeshita A. Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action. Circulation. 1999;100:690–2.PubMedCrossRefGoogle Scholar
  28. 28.
    Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharamacol. 1991;31:1061–9.CrossRefGoogle Scholar
  29. 29.
    Sakamoto J, Miura T, Tsuchida A, Fukuma T, Hasegawa T, Shimamoto K. Reperfusion arrhythmias in the murine heart: their characteristics and alteration after ischemic preconditioning. Basic Res Cardiol. 1999;94:489–95.PubMedCrossRefGoogle Scholar
  30. 30.
    Tzivoni D, Keren A, Granot H, Gottlieb S, Benhorin J, Stern S. Ventricular fibrillation caused by myocardial reperfusion in Prinzmetal’s angina. Am Heart J. 1983;105:323–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Hiroyuki Takahama
    • 2
    • 5
  • Hirokazu Shigematsu
    • 3
  • Tomohiro Asai
    • 3
  • Takashi Matsuzaki
    • 1
  • Shoji Sanada
    • 1
  • Hai Ying Fu
    • 1
  • Keiji Okuda
    • 1
  • Masaki Yamato
    • 1
  • Hiroshi Asanuma
    • 4
  • Yoshihiro Asano
    • 1
  • Masanori Asakura
    • 2
  • Naoto Oku
    • 3
  • Issei Komuro
    • 1
  • Masafumi Kitakaze
    • 2
  • Tetsuo Minamino
    • 1
  1. 1.Department of Cardiovascular MedicineOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Department of Cardiovascular MedicineNational Cerebral and Cardiovascular CenterSuitaJapan
  3. 3.Department of Medical Biochemistry and Global COEUniversity of Shizuoka Graduate School of Pharmaceutical SciencesShizuokaJapan
  4. 4.Department of Cardiovascular Science and TechnologyKyoto Prefectural University School of MedicineKyotoJapan
  5. 5.Division of Cardiovascular DiseaseMayo ClinicRochesterUSA

Personalised recommendations